×
Shares of iRhythm Holdings dropped -21.42%, sliding from a prior close of $130.19 to roughly $102.30 in Thursday's regular session after gapping down in after-hours trading. Third-quarter results released after Wednesday's close disappointed: revenue of $221.6M narrowly missed estimates, and management delayed the next-generation Zio MCT launch timeline while flagging flat Zio AT revenue.
GMED slid -9.09%, falling from its previous close of $81.44 to $74.04 during regular market hours on November 6. The drop extended the selloff after Q3 results released after the close on November 5: revenue of $763.7M missed consensus and the company cut full-year 2026 revenue guidance to $3.09B, its first cut of the year.
SINTX Technologies reported third-quarter 2026 revenue of approximately $2.2 million, up 953% from $208,000 a year earlier, driven by aerospace technical manufacturing sales. Gross profit climbed to roughly $1.4 million, with gross margin expanding to 62% from 45% in the prior-year quarter.
Net sales from continuing operations rose 20.4% year over year to $1.1 million, led by 20% growth in the cardiovascular business. Total net loss narrowed to $1.3 million, or $0.03 per basic share, from $3.9 million a year earlier, helped by $5.2 million in income from discontinued operations.
Third-quarter 2026 revenue came in at $13.8 million, below the roughly $13.94 million consensus estimate, while EPS (earnings per share) was a loss of $0.52 versus the approximately $0.50 loss analysts expected. Full-year 2026 revenue guidance was lowered to a range of $56 million to $57 million, down from the prior $58 million to $60 million.
Sensus Healthcare is expected to report third-quarter 2026 results after the market closes on November 12, 2026, with a conference call to follow. Consensus estimates point to a loss of roughly $0.06 per share on revenue near $6.61 million, compared with a loss of $0.06 per share and revenue of $6.88 million in the year-ago quarter.
LENSAR, Inc. is scheduled to report its third quarter 2026 results before the market opens on Tuesday, November 10, 2026, with a conference call at 8:30 a.m. ET. Consensus estimates call for a net loss of about $0.095 per share on revenue of roughly $14.30 million.
Global net revenue reached €9.2 million in the third quarter of 2026, up 365% year over year and 19% sequentially, driven by U.S. net revenue of €6.7 million. Gross margin improved to 63.1% from 60.5% a year earlier, while the operating loss narrowed to €21.9 million from €24.4 million.
Apyx Medical reported third quarter 2026 revenue of $14.0 million, up 9% year over year and above the consensus estimate of roughly $13.3 million. The company posted a net loss of $0.04 per share, narrower than the $0.07 loss analysts had expected and an improvement from the $0.05 loss in the prior-year quarter.
Inogen reported third quarter 2026 revenue of $77.2 million , down 2.4% from $79.1 million in the prior-year period. U.S. sales rose 3.8% to $42.2 million, marking the first year-over-year U.S. growth since the fourth quarter of 2024.
Third-quarter 2026 revenue rose 73% year over year to $15.6 million, exceeding the consensus estimate of roughly $15.35 million. Net loss widened to $17.3 million, or $0.52 per diluted share, compared with $11.4 million, or $13.31 per share, in the prior-year period.
Silvergate Capital Corporation emerged from Chapter 11 bankruptcy on March 31, 2026, more than three years after winding down its crypto-focused bank. The company published its fiscal 2025 financial results on August 8, 2026, a disclosure tied to its stock uplisting rather than to an ongoing operating business.
Cochlear reported fiscal 2026 (year ended 30 June 2026) sales revenue of A$2,343.4 million, up 2% in constant currency, with underlying net profit of A$322.4 million landing at the upper end of revised guidance. Statutory net profit fell 62% to A$147.3 million, weighed down by significant non-cash items, including cloud-related investment and innovation-fund write-downs.
Artivion reported third quarter 2026 revenue of $123.8 million , up 9% on a constant currency basis and above the consensus estimate of roughly $121 million. Non-GAAP (adjusted) diluted EPS came in at $0.08 , beating the consensus estimate of about $0.07 per share.
Enovis reported third-quarter net sales of $558.7 million , up 1.8% year over year (5% organic), essentially in line with consensus estimates. Adjusted earnings per share (EPS) came in at $0.88 , up 17% year over year and comfortably above the roughly $0.77 Wall Street consensus.
Worldwide sales rose 14% year over year to $283.7 million, beating analyst consensus estimates. Net loss narrowed to $7.1 million, or $0.10 per share, from $21.2 million, or $0.31 per share, a year earlier.
TransMedics Group reported third quarter 2026 revenue of $203 million, up 41% year over year (YoY) and its highest quarterly revenue on record, topping analyst expectations. Non-GAAP (adjusted) earnings per share (EPS) came in at $0.51, well above the consensus estimate, while GAAP (generally accepted accounting principles) diluted EPS was $0.46.
Third quarter 2026 revenue rose 14.9% year over year to $221.6 million, roughly in line with the analyst consensus of about $222.3 million. Adjusted (non-GAAP) earnings per share (EPS) reached $0.82, far above the roughly $0.05 analysts had expected, driven by a sharp margin expansion.
Haemonetics reported fiscal second-quarter 2027 revenue of $357.8 million, up 9.3% year over year and ahead of the roughly $346.8 million consensus estimate. Adjusted earnings per share (EPS) rose 6% to $1.35, topping the $1.30 analyst consensus, while GAAP (Generally Accepted Accounting Principles) EPS climbed 23% to $1.00.
Third quarter revenue reached $150.7 million , up 1.1% year over year and slightly above the roughly $148 million consensus estimate. GAAP net loss narrowed to -$0.15 per share , beating the consensus estimate of about -$0.26 per share.
Previous
14 of 31
Next